Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.46 |
| ▸ | PREP | P48147 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4447020 | 0.97 | HRH3 (0.50) | HRH3KCNH2HSD17B10 | |
| SCHEMBL4448614 | 0.97 | HRH3 (0.50) | HRH3KCNH2HSD17B10 | |
| SCHEMBL4448644 | 0.97 | HRH3 (0.48) | HRH3KCNH2PREPHSD17B10HPGD | |
| SCHEMBL4453012 | 0.97 | HRH3 (0.50) | HRH3KCNH2HSD17B10 | |
| SCHEMBL4450543 | 0.93 | HSD17B10 (0.46) | HRH3KCNH2PREPHSD17B10CHRM2 | |
| SCHEMBL4449652 | 0.93 | HSD17B10 (0.46) | HRH3KCNH2PREPHSD17B10CHRM2 | |
| SCHEMBL2496643 | 0.89 | HSD17B10 (0.50) | PREPHSD17B10CHRM2CHRM1CHRM3 | |
| SCHEMBL13462044 | 0.87 | HPGD (0.50) | PREPHSD17B10CHRM2CHRM1CHRM3 | |
| SCHEMBL2709135 | 0.87 | HPGD (0.50) | PREPHSD17B10CHRM2CHRM1CHRM3 | |
| SCHEMBL7142429 | 0.85 | HPGD (0.52) | PREPHSD17B10CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236792-B2 | Substituted pyrrolidine amides as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-07 | — | — | US | claimed |
| US-20090291903-A1 | SUBSTITUTED PYRROLIDINE AMIDES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-11-26 | — | — | US | claimed |
| US-8236792-B2 | Substituted pyrrolidine amides as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-07 | — | — | US | disclosed |
| US-8236792-B2 | Substituted pyrrolidine amides as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-07 | — | — | US | disclosed |
| US-8236792-B2 | Substituted pyrrolidine amides as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-07 | — | — | US | disclosed |
| WO-2009143153-A1 | SUBSTITUTED PYRROLIDINE AMIDES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-26 | — | — | WO | disclosed |
| US-20090291903-A1 | SUBSTITUTED PYRROLIDINE AMIDES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-11-26 | — | — | US | disclosed |
| US-20090291903-A1 | SUBSTITUTED PYRROLIDINE AMIDES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-11-26 | — | — | US | disclosed |
| US-20090291903-A1 | SUBSTITUTED PYRROLIDINE AMIDES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291903-A1 | SUBSTITUTED PYRROLIDINE AMIDES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH2 | HRH3 1/4885KCNH2 1338/4885PREP 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.